2022 American Transplant Congress
Evaluation of the Management of Cytomegalovirus in Kidney Transplant Recipients After Establishment of a Multidisciplinary Cytomegalovirus Workgroup
Hennepin County Medical Center, Minneapolis, MN
*Purpose: To assess the effectiveness of a multidisciplinary cytomegalovirus (CMV) workgroup in managing CMV in kidney transplant recipients.*Methods: Retrospective chart review at a single transplant…2022 American Transplant Congress
Ultra-Short Duration Prophylaxis for Hepatitis C Donor Positive to Recipient Negative Simultaneous Kidney/Pancreas Transplants
Virginia Commonwealth University, Richmond, VA
*Purpose: Recent trials have successfully utilized a strategy of hepatitis C virus (HCV) D+ [Donor nucleic acid test (NAT) positive]/R- (Recipient NAT negative) kidney and/or…2022 American Transplant Congress
Preemptive Therapy for Cytomegalovirus (CMV) Disease Prevention in High-Risk CMV Donor Seropositive Recipient Seronegative (D+/R-) Liver Transplant Recipients in a Real-World Setting
*Purpose: Preemptive therapy (PET) has demonstrated superiority to antiviral prophylaxis for prevention of cytomegalovirus (CMV) disease in CMV donor seropositive/recipient seronegative (D+R-) liver transplant recipients …2022 American Transplant Congress
Use of Targeted T-Cell Therapy (Posoleucel) for the Treatment of Epstein-Barr Virus Associated Leiomyosarcoma in an Adult Kidney Transplant Recipient: A Case Report
*Purpose: Epstein-Barr virus (EBV)-associated leiomyosarcomas (EBV+LMS) are neoplasms rarely seen in solid organ transplant (SOT) recipients and currently lack effective treatment options. We present a…2022 American Transplant Congress
Impact of Dysgeusia on Transplant Recipients with Refractory Cytomegalovirus with/without Resistance Receiving Maribavir: Post-Hoc Analyses from a Phase 3 Randomized Trial
*Purpose: In a Phase 3 study (SOLSTICE; NCT02931539), maribavir (MBV) was superior to investigator-assigned therapies (IAT; val/ganciclovir, foscarnet, or cidofovir) for CMV clearance at Wk…2022 American Transplant Congress
Immunoglobulin M (IgM) Inhibits Replication of SARS-CoV-2 In Vero E6 Cells In Vitro and Delays Disease in K18-hACE2 Mice Infected with SARSCoV-2 In Vivo
*Purpose: To determine if IgM has a direct effect in preventing SARS-CoV-2 replication in Vero E6 cells, and delaying or preventing disease in infected K18-hACE2…2022 American Transplant Congress
Adenosine A2A Receptor (A2AR) Agonist Apadenoson Promotes Survival in K28-hACE2 Mice and Syrian Hamsters Infected with Sars-CoV-2
*Purpose: To determine if Apadenoson or Regadenoson has a therapeutic effect in attenuating hyper-inflammation and improving survival rate in K18-hACE2mice or Syrian hamsters infected with…2022 American Transplant Congress
Metagenomic Next-Generation Sequencing Reveals the Profile of Viral Infections in Kidney Transplant Recipients During the Covid-19 Pandemic
Henan Province People's Hospital, Zhengzhou, Henan Province, China
*Purpose: To study the clinical application of metagenomic next-generation sequencing (mNGS) in the detection of viral infections in kidney transplant recipients (KTRs) during the COVID-19…2022 American Transplant Congress
Management of Hepatitis B Positive Donors in Liver Transplant
1Pharmacy, UAB, Birmingham, AL, 2UAB, Birmingham, AL
*Purpose: In an effort to expand the pool of solid organ transplant donors, patients with end stage liver disease may receive an organ from a…2022 American Transplant Congress
Transplantation of Hepatitis C Viremic Donor Organs to Hepatitis C Nonviremic Recipients: A Retrospective Review
*Purpose: The advent of combination direct-acting antiviral (DAA) agents has improved the ability to treat hepatitis C virus (HCV) infections. As a result, utilization of…
- 1
- 2
- 3
- …
- 14
- Next Page »